GLYCOTOPE is a global leader in Glycobiology and is developing new and propietary biopharmaceuticals with optimized and fully human glycosylation structures as well as highly specific antibodies against glyco-epitopes on cancer cells.
With GlycoExpress and the GlycoBody technologies Glycotope has one of the broadest platforms for the development and production of glycosylated proteins.
A clinical pipeline of 4 glycooptimized and fully human glycosylated NBEs underlines GLYCOTOPE´s and its manufacturing arm GLYCOTOPE BIOTECHNOLOGY´s competence to contribute significant improvements to healthcare.